Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
3.82(c) 3.99(c) 4.5(c) 4.45(c) 4.57(c) Last
34 670 70 077 98 025 60 776 872 054 Volume
+6.70% +4.45% +12.78% -1.11% +2.70% Change
More quotes
Financials ($)
Sales 2017 2,24 M
EBIT 2017 -47,7 M
Net income 2017 -46,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,18 M
EBIT 2018 -63,8 M
Net income 2018 -62,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 36,6x
Capi. / Sales2018 11,4x
Capitalization 82,1 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company.It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company operates through two segments: Consumer Operations and Drug Development.The... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
06/15 FLEX PHARMA : Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the ..
06/06 FLEX PHARMA, INC. : Change in Directors or Principal Officers, Submission of Mat..
06/05 FLEX PHARMA : Announces Executive Leadership Transition
06/03 FLEX PHARMA : FLKS) Announces Endorsement of Phase 2 Trial with FLX-787 in Charc..
06/03 FLEX PHARMA : Pharmas Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed..
06/02 FLEX PHARMA : Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the ..
05/30 FLEX PHARMA : Presenting at Upcoming Investor Conferences in June 2017
05/03 FLEX PHARMA : Management's Discussion and Analysis of Financial Condition and Re..
05/03 FLEX PHARMA, INC. (NASDAQ : FLKS) Files An 8-K Results of Operations and Financi..
05/03 FLEX PHARMA, INC. : Results of Operations and Financial Condition (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/14Flex Pharma $FLKS Earning Somewhat Critical Press Coverage, AlphaOne Reports .. 
06/10Analysts Set Flex Pharma Inc $FLKS Price Target at $17.50  
06/07Get the latest ratings for $BZUN $OIBR $VIAS $SURG $FLKS in your inbox with M.. 
06/06Tiny Flex Pharma’s CEO Westphal steps down -  
06/06Christoph Westphal finds the exit at his latest biotech creation — after the .. 
More tweets
Qtime:14
News from SeekingAlpha
06/12 Midday Gainers / Losers
06/05 New chief at Flex Pharma; shares slip 4% after hours
05/03 Flex Pharma beats by $0.13, misses on revenue
05/02 VC-BACKED IPOS IN PRIVATE BIOTECH : Murky, With Many Shades Of Black
04/26 FDA OK's Flex Pharma's IND for ALS candidate FLX-787; Phase 2 study on tap fo..
Advertisement
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Full-screen chart
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,8 $
Spread / Average Target 311%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christoph H. Westphal Chairman, President & Chief Executive Officer
Katharine G. Lindemann Chief Operating Officer
John McCabe Chief Financial Officer & Treasurer
Thomas C. Wessel Chief Medical Officer
William K. McVicar President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC-13.45%82
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results